Sabrina Boyte
Physician Assistant · Morehead City, NCNPI 1033284559
Payments from drug & device makers
Across 147 payments — averaging $42.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$2K
- Abbott$834
- Amgen$515
- AstraZeneca$501
- Novo Nordisk$420
- Bayer$363
- plus $2K from 28 others
Across 11 payments — averaging $158.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Speaking & faculty fees$2,00032%
- Food & beverage$4,30968%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 8 | $2,101 |
| Abbott | 42 | $834 |
| Amgen | 14 | $515 |
| AstraZeneca | 6 | $501 |
| Novo Nordisk | 8 | $420 |
| Bayer | 16 | $363 |
| Cequr Corporation | 2 | $140 |
| Lilly USA, LLC | 8 | $135 |
| Pfizer | 1 | $124 |
| AbbVie | 7 | $122 |
| Gilead | 1 | $100 |
| Dexcom, Inc. | 1 | $96 |
| Phathom Pharmaceuticals, Inc. | 1 | $95 |
| Nevro Corp. | 4 | $91 |
| Axonics, Inc. | 2 | $83 |
| Medtronic | 1 | $79 |
| BD | 1 | $71 |
| Corcept Therapeutics | 4 | $69 |
| Boston Scientific | 2 | $68 |
| BETA Bionics, Inc. | 2 | $43 |
| Lifescan, Inc. | 2 | $37 |
| Mannkind Corporation | 2 | $30 |
| Sequel Med Tech, LLC | 1 | $27 |
| Merck | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Novartis | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$2,000
- EVENITY$250
- FARXIGA$236
- Wegovy$221
- BREZTRI$125
- Repatha$125
- Kerendia$125
- NURTEC ODT$124
- CeQur Simplicity$119
- FREESTYLE LIBRE 3$119
- FreeStyle Libre 2$109
- Epclusa$100
How this compares
$6,309 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 179 | $315,779 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 50 | $86,142 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $82,567 |
| FarxigaDapagliflozin Propanediol | 84 | $78,360 |
| JardianceEmpagliflozin | 47 | $58,676 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $49,975 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 31 | $49,006 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $44,250 |
| Xigduo XrDapaglifloz Propaned/Metformin | 38 | $43,846 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $42,982 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 16 | $41,128 |
| Tresiba Flextouch U-100Insulin Degludec | 63 | $38,425 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $34,404 |
| Humulin R U-500Insulin Regular, Human | 16 | $23,119 |
| MounjaroTirzepatide | 20 | $20,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $420 | $331,987214 claims |
| AstraZenecaFarxiga | $501 | $78,36084 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $13 | $49,97536 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $135 | $49,58798 claims |
| MerckJanumet Xr | $19 | $19,55620 claims |
| Johnson & JohnsonInvokana | $14 | $6,54711 claims |
| AbbVieSynthroid, Armour Thyroid | $122 | $4,24543 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,205161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Morehead City
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.